Literature DB >> 28270366

Immune defects caused by mutations in the ubiquitin system.

Amos Etzioni1, Aaron Ciechanover2, Eli Pikarsky3.   

Abstract

The importance of the ubiquitin system in health and disease has been widely recognized in recent decades, with better understanding of the various components of the system and their function. Ubiquitination, which is essential to almost all biological processes in eukaryotes, was also found to play an important role in innate and adaptive immune responses. Thus it is not surprising that mutations in genes coding for components of the ubiquitin system cause immune dysregulation. The first defect in the system was described 30 years ago and is due to mutations in the nuclear factor κB (NF-κB) essential modulator, a key regulator of the NF-κB pathway. With use of novel sequencing techniques, many additional mutations in different genes involved in ubiquitination and related to immune system function were identified. This can be clearly illustrated in mutations in the different activation pathways of NF-κB, which result in aberrations in production of various proinflammatory cytokines. The inherited diseases typically manifest with immunodeficiency, autoimmunity, or autoinflammation. In this perspective we provide a short description of the ubiquitin system, with specific emphasis given to its role in the immune system. The various immunodeficiency conditions identified thus far in association with defective ubiquitination are discussed in more detail.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ubiquitin; immunodeficiency; nuclear factor κB

Mesh:

Substances:

Year:  2017        PMID: 28270366     DOI: 10.1016/j.jaci.2016.11.031

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms.

Authors:  Yelena Kravtsova-Ivantsiv; Gilad Goldhirsh; Alexandra Ivantsiv; Ofer Ben Itzhak; Yong Tae Kwon; Eli Pikarsky; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-09       Impact factor: 11.205

Review 2.  Ubiquitin-related processes and innate immunity in C. elegans.

Authors:  Juan A Garcia-Sanchez; Jonathan J Ewbank; Orane Visvikis
Journal:  Cell Mol Life Sci       Date:  2021-02-25       Impact factor: 9.261

3.  6-O-angeloylplenolin inhibits anti-IgE-stimulated human mast cell activation via suppressing calcium influx and ERK phosphorylation.

Authors:  Yangyang Yu; Dongxu Lin; Zhenyu Liu; Ran Fang; Siman Zheng; Yongxian Cheng; Zhong Huang; Chun Wai Ng; Hang Yung Alaster Lau
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

4.  USP15 Deubiquitinates CARD9 to Downregulate C-Type Lectin Receptor-Mediated Signaling.

Authors:  Wenting Xu; Jason S Rush; Daniel B Graham; Zhifang Cao; Ramnik J Xavier
Journal:  Immunohorizons       Date:  2020-10-22

5.  OTULIN deficiency in ORAS causes cell type-specific LUBAC degradation, dysregulated TNF signalling and cell death.

Authors:  Rune Busk Damgaard; Paul R Elliott; Kirby N Swatek; Eamonn R Maher; Polina Stepensky; Orly Elpeleg; David Komander; Yackov Berkun
Journal:  EMBO Mol Med       Date:  2019-03       Impact factor: 12.137

6.  Global transcriptional regulation of STAT3- and MYC-mediated sepsis-induced ARDS.

Authors:  Jianfeng Zhang; Yifeng Luo; Xiaoling Wang; Jieyun Zhu; Qian Li; Jihua Feng; Dan He; Zhimei Zhong; Xiaowen Zheng; Junyu Lu; Donghua Zou; Jiefeng Luo
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

7.  A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.

Authors:  Peng Li; Shobi Venkatachalam; Daniela Ospina Cordona; Lorena Wilson; Tibor Kovacsovics; Karen A Moser; Rodney R Miles; David B Beck; Tracy George; Srinivas K Tantravahi
Journal:  Blood Adv       Date:  2022-01-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.